Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (17022)	12/17/1998 10:04:00 AM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

Dais...THERE WERE NO MILESTONE PAYMENTS in the 3rd QTR..... The $8 mill in A/R was for sale of Muse to Astra/Janssen, etc. The press release today also clarifies that VVUS gets $2 million as each country Italy, France, Spain, Germany licence Muse for a total of $8 million. And Australia approval is a nice Holiday Bonus....

To: DaiS who wrote (17022)	12/17/1998 10:12:00 AM
From: VLAD	Respond to of 23519

Dave, Wasn't me but I remember someone saying 30 days from the date that Astra got EU approval which was December 1. Evidently this can't be true because the press release suggests 1999 Q1 and Q2 to realize these milestones. Andreas Samson suggested that the $8M was included in the accounts receivable as mentioned in the SEC Q10 filing. This was an erroneous statement on AS's part. Hope that helps. All in all, it looks to me like potential in foreign revenue should be excellent in 1999. A good partnering deal domestically should get Vivus back into double digits in 1999.